EXACT Therapeutics first half 2025 interim results

25 Sep 2025 08:00 CEST

25 September, 2025: EXACT Therapeutics AS (“EXACT-Tx”, Euronext Growth: EXTX), a
clinical stage precision health company utilising Acoustic Cluster Therapy
(ACT®) across multiple therapeutic areas, today announces its interim results
for the first half 2025.

The interim report for the first half year 2025 is also available on the
company's website: www.exact-tx.com.

For further information, please contact:
Per Walday
CEO EXACT Therapeutics
Email: per.walday@exact-tx.com

John M. Edminson
CFO EXACT Therapeutics
Email: john.edminson@exact-tx.com

About EXACT Therapeutics:
EXACT Therapeutics is a clinical-stage precision medicine company utilizing the
power of ultrasound and microbubbles to enable targeted drug delivery in
oncology. Acoustic Cluster Therapy (ACT®) follows a unique approach and may be
applied to a wide range of therapeutic agents within oncology and across a
multitude of other indications, including brain diseases. EXACT Therapeutics’
shares are traded on Euronext Growth Oslo (EXTX). Further information may be
found here: www.exact-tx.com

More information:
Access the news on Oslo Bors NewsWeb site

656093_EXACT Therapeutics 1H 2025 Financial report.pdf